scholarly journals Pigmentation and Scaring Management after Hypodermoclysis, a Case Report

Cosmetics ◽  
2022 ◽  
Vol 9 (1) ◽  
pp. 10
Author(s):  
Kamal Alhallak ◽  
Adel Abdulhafid ◽  
Salem Tomi ◽  
Dima Omran
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Skin Diseases ◽  
Skin Lesions ◽  
Subcutaneous Infusion ◽  
Laser Technology ◽  
Dermal Tissue ◽  
Continuous Subcutaneous Infusion ◽  
Laser Treatments ◽  
Cutaneous Damage

Hypodermoclysis is the continuous subcutaneous infusion of a parenteral solution into dermal tissue, which is typically associated with skin lesions and cosmetic issues in the majority of patients. Scarring and pigmentation are two of the potential skin lesions after hypodermoclysis. The way skin diseases and cosmetic issues are treated has altered dramatically as a result of laser technology. This is the first article to our knowledge that describes the treatment of pigmentation and scarring produced by Hypodermoclysis cutaneous damage by using laser treatment. It was vital to select the appropriate endpoint, technology, and configuration parameters. The lesion was completely resolved after five months of treatment with four laser sessions. The first session used a fractional Er-Yag laser to perform cold ablation. The remaining sessions used 1064 and 585 nm Nd-Yag Q-switch lasers to operate in the nanosecond region. To minimize the danger of post-inflammatory hyperpigmentation (PIH), the treated region was prepped between laser treatments with 4% hydroquinone (HQ) cream. Our protocol may reduce scars and pigmentation while minimizing adverse effects and downtime.

scholarly journals Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Per Fürst ◽  
Staffan Lundström ◽  
Pål Klepstad ◽  
Peter Strang
Keyword(s):  
Palliative Care ◽  
Adverse Effects ◽  
Pain Control ◽  
Performance Status ◽  
Infusion Pump ◽  
Eastern Cooperative Oncology Group ◽  
Moderate Increase ◽  
Subcutaneous Infusion ◽  
Dying Patients ◽  
Continuous Subcutaneous Infusion

Abstract Background Continuous subcutaneous infusion (CSCI) via ambulatory infusion pump (AIP) is a valuable method of pain control in palliative care. When using CSCI, low-dose methadone as add-on to other opioids might be an option in complex pain situations. This study aimed to investigate the effects, and adverse effects, of CSCI for pain control in dying patients, with particular interest in methadone use. Methods This was an observational cohort study. Imminently dying patients with pain, admitted to specialized palliative inpatient wards and introduced on CSCI, were monitored daily by staff for symptoms (Integrated Palliative Care Outcome Scale - IPOS), sedation (Richmond Agitation and Sedation Scale – RASS), performance status (Eastern Cooperative Oncology Group - ECOG) and delirium (Confusion Assessment Method - CAM). Results Ninety-three patients with a median survival of 4 days were included. Of the 47 patients who survived ≥3 days, the proportion of patients with severe/overwhelming pain decreased from 45 to 19% (p < 0.001) after starting CSCI, with only a moderate increase in morphine equivalent daily dose of opioids (MEDD). Alertness was marginally decreased (1 point on the 10-point RASS scale, p = 0.001), whereas performance status and prevalence of delirium, regardless of age, remained unchanged. Both patients with methadone as add-on (MET, n = 13) and patients with only other opioids (NMET, n = 34), improved in pain control (p < 0.05 and 0.001, respectively), despite that MET patients had higher pain scores at baseline (p < 0.05) and were on a higher MEDD (240 mg vs.133 mg). No serious adverse effects demanding treatment stop were reported. Conclusions CSCI via AIP is an effective way to reduce pain in dying patients without increased adverse effects. Add-on methadone may be beneficial in patients with severe complex pain.

Continuous Subcutaneous Infusion of Ketorolac in Cancer Neuropathic Pain Unresponsive to Opioid and Adjuvant Drugs. A Case Report

1996 ◽  
Vol 82 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Carla Ripamonti ◽  
Chiara Ticozzi ◽  
Ernesto Zecca ◽  
Carlos H. Rodriguez ◽  
Franco De Conno
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Side Effects ◽  
Cancer Patient ◽  
Cancer Pain ◽  
Antidepressant Drugs ◽  
Analgesic Efficacy ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion ◽  
Nonopioid Analgesic

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

scholarly journals DAPSONE HYPERSENSITIVITY SYNDROME - A CASE REPORT

2014 ◽  
Vol 04 (03) ◽  
pp. 124-126
Author(s):  
Aneseya P. Varghese ◽  
Deepthi R. V. ◽  
Vijaya Shenoy ◽  
Seema Pavaman
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Hypersensitivity Syndrome ◽  
Skin Lesions ◽  
Low Grade ◽  
Salient Features ◽  
Systemic Examination

AbstractDapsone is widely used for a variety of infectious, immune and hypersensitivity disorders. However, the use of dapsone may be associated with a plethora of adverse effects.We are reporting a 6 year old who was treated with dapsone for one month. He presented to us with low grade fever and skin lesions all over body with normal systemic examination. He was evaluated and was diagnosed as having Dapsone Hypersensitivity Syndrome (DHS) and treated with steroids.The incidence of DHS ranges from 0.5% to3%. DHS can present as early as 7–10 days after administration of the drug uptil 6 months into. therapy DHS must be promptly identified, asUntreated the disorder could be fatal. This syndrome is best approached with the immediate discontinuation of the offending drug and prompt administration of oral or intravenous glucocorticoids.Since dapsone is used for various indications, the salient features about the syndrome and its management should be familiarized.

scholarly journals Acrodermatitis due to zinc deficiency after combined vertical gastroplasty with jejunoileal bypass: case report

2012 ◽  
Vol 130 (5) ◽  
pp. 330-335 ◽  
Author(s):  
Selma Freire de Carvalho Cunha ◽  
Gilson Antônio Pereira Gonçalves ◽  
Julio Sérgio Marchini ◽  
Ana Maria Ferreira Roselino
Keyword(s):  
Bariatric Surgery ◽  
Case Report ◽  
Skin Diseases ◽  
Jejunoileal Bypass ◽  
Skin Lesions ◽  
Nutritional Deficiencies ◽  
Acrodermatitis Enteropathica ◽  
Vertical Gastroplasty ◽  
Treatment Of Obesity ◽  
Zinc Levels

CONTEXT: Nutritional complications may occur after bariatric surgery, due to restriction of food intake and impaired digestion or absorption of nutrients. CASE REPORT: After undergoing vertical gastroplasty and jejunoileal bypass, a female patient presented marked weight loss and protein deficiency. Seven months after the bariatric surgery, she presented dermatological features compatible with acrodermatitis enteropathica, as seen from the plasma zinc levels, which were below the reference values (34.4 mg%). The skin lesions improved significantly after 1,000 mg/day of zinc sulfate supplementation for one week. CONCLUSIONS: The patient's evolution shows that the multidisciplinary team involved in surgical treatment of obesity should take nutritional deficiencies into consideration in the differential diagnosis of skin diseases, in order to institute early treatment.

Anticoagulation by Constant Subcutaneous Heparin Infusion

1982 ◽  
Vol 47 (01) ◽  
pp. 001-002 ◽  
Author(s):  
Nenita Parrilla ◽  
Jack Ansell
Keyword(s):  
Clinical Trial ◽  
Impedance Plethysmography ◽  
High Dose ◽  
Intravenous Therapy ◽  
Heparin Dose ◽  
Heparin Infusion ◽  
Subcutaneous Infusion ◽  
Subcutaneous Heparin ◽  
Therapeutic Anticoagulation ◽  
Continuous Subcutaneous Infusion

SummaryA preliminary clinical trial was conducted to determine the feasibility of achieving and regulating therapeutic anticoagulation with heparin given by continuous subcutaneous infusion. Five patients with deep venous thrombosis confirmed by impedance plethysmography and/or venography were studied. All patients received an initial heparin dose of 5000 units by IV bolus. This was followed by a continuous subcutaneous heparin infusion at a dose of 15 to 25 units per kilogram per hour. Effective levels of anticoagulation were achieved in all five patients. Regulation and maintenance of therapeutic anticoagulation were no more difficult than with intravenous therapy. No major complications were encountered during therapy.Continuous subcutaneous infusion of heparin may have advantages over standard intravenous therapy or high dose intermittent subcutaneous therapy. However, more extensive clinical evaluation is warranted.

scholarly journals Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report

2021 ◽  
pp. 379-383
Author(s):  
Meghan L. McPhie ◽  
Kevin Y.M. Ren ◽  
J. Michael Hendry ◽  
Sonja Molin ◽  
Thomas Herzinger
Keyword(s):  
Case Report ◽  
Hepatitis C ◽  
Adverse Effects ◽  
Hypersensitivity Reaction ◽  
Allergic Reaction ◽  
Delayed Type Hypersensitivity ◽  
Histological Features

Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with the initiation of ledipasvir/sofosbuvir treatment for his hepatitis C. Clinical and histological features were consistent with a delayed-type hypersensitivity reaction to red ink.

scholarly journals Plaque erosion causing ST-elevation myocardial infarction after consumption of cannabis and N2O in a 27-year old man: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sarah Bär ◽  
Fabien Praz ◽  
Lorenz Räber
Keyword(s):  
Myocardial Infarction ◽  
Case Report ◽  
Adverse Effects ◽  
Cardiovascular Effects ◽  
Drug Eluting Stent ◽  
Culprit Lesion ◽  
Vascular Events ◽  
The Public ◽  
Plaque Erosion ◽  
First Case

Abstract Background The recreational drugs cannabis and nitrous oxide (N2O) are known for pro-atherogenic effects and are associated with an elevated risk of myocardial infarction. These cardiovascular effects might be underestimated by the public. Culprit-lesion composition of myocardial infarctions associated with cannabis and N2O has been unknown so far. This case report aims to raise the awareness of the adverse cardiovascular effects of cannabis and N2O and reports, for the first time, optical coherence tomography (OCT) findings of the culprit lesion. Case presentation This is a case report of a 27-year old man with anterior ST-segment-elevation myocardial infarction (STEMI) after intoxication with cannabis and N2O. Coronary angiography and OCT revealed plaque erosion with subsequent subtotal thrombotic occlusion of the left anterior descending artery that was successfully treated with 1 drug-eluting stent. The patient was symptom free at 6 months follow-up and had been able to abstain from drug consumption. Conclusions This is the first case to demonstrate the association between cannabis and N2O abuse and plaque erosion on OCT in a young man with STEMI. In contrast to smoking, whose adverse effects are well-known, the cardiovascular effects of cannabis and N2O might be underestimated. These adverse effects should gain more awareness in the public to prevent early vascular events in young adults.

Sign in / Sign up

Export Citation Format

Share Document